Head to Head Contrast: IM Cannabis (NASDAQ:IMCC) vs. MediciNova (NASDAQ:MNOV)

IM Cannabis (NASDAQ:IMCC) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Institutional and Insider Ownership

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares IM Cannabis and MediciNova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	-585.96%	-58.32%
MediciNova	-1,168.70%	-26.51%	-24.39%

Risk & Volatility

IM Cannabis has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for IM Cannabis and MediciNova, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1	0	0	0	1.00
MediciNova	1	1	3	1	2.67

MediciNova has a consensus price target of $8.33, suggesting a potential upside of 480.72%. Given MediciNova’s stronger consensus rating and higher probable upside, analysts plainly believe MediciNova is more favorable than IM Cannabis.

Valuation and Earnings

This table compares IM Cannabis and MediciNova”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17 million	0.02	-$8.10 million	($2.02)	-1.69
MediciNova	$410,000.00	172.27	-$12.00 million	($0.21)	-6.83

IM Cannabis has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

MediciNova beats IM Cannabis on 10 of the 15 factors compared between the two stocks.

About IM Cannabis

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

About MediciNova

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.